Lacosamida Tecnigen (Lacosamide)

Lacosamide is an anticonvulsant that targets voltage‑gated sodium channels to control seizure activity.

• Partial‑onset seizures: reduces seizure frequency when added to existing therapy.
• Focal seizures: improves seizure control as an adjunctive agent.
• Epilepsy (adjunctive therapy): enhances overall management of refractory epilepsy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and diminishes repetitive neuronal firing. By selectively targeting the sodium channel's inactivated state, it reduces the propagation of epileptiform activity without significantly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Fatigue: feeling unusually tired or weak.
• Diplopia: transient double vision.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Cardiac arrhythmias: abnormal heart rhythms, especially in patients with pre‑existing conduction disorders.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Severe hypersensitivity: rash, swelling, or anaphylaxis.
• Cardiac conduction abnormalities: PR‑interval prolongation or atrioventricular block.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Cardiac monitoring: assess ECG in patients with known conduction disease.
• Renal function: adjust dosing in severe renal impairment.
• Hepatic function: use caution in moderate to severe liver disease.
• Pregnancy: avoid unless benefit outweighs potential risk; data are limited.
• Discontinuation: taper gradually to reduce seizure recurrence.
• Store at ambient temperature: keep in original container, protect from moisture and direct light.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide exposure.
• Other sodium‑channel blockers (e.g., lamotrigine): increase risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may enhance cognitive side effects.
• CNS depressants (e.g., benzodiazepines, opioids): may increase sedation and dizziness.